you don't need to go to a chat room all the pumpers are here and they have over run the site with BS. Great for daytraders
The only reason to buy here is if you want to begin to accumulate a position. The company needs money so there will be dilutive financing soon and that is the only thing you can count on 100%. This company has great science, however, as they have been at this for 15 years 10 years as cytori and failed miserably every step of the way, I assure you this will not run away from you. There is plenty of competition and I feel that the head start Cytori had over them has faded due to timing. Go to cytx-investor site and read up on the history and multude of failures. You will never buy at the low nor sell at the high. Management is not to be trusted.
Go back listen to the call from other day and look at Maxim report and own report from CYTX on revenue numbers,the come back and post.
We alreaady know from the presentation this week that Earnings call is not going to be good and that they missed numbers so it's no secret. Stock is being controlled by Sabby so if they want it above it will stay,if they want it below it will be. This stock not trading on results as there really have been none just a new set of promises and hope that the old ones that have been broken will be forgotten. Which they have not been by long term holders and are irrelevant to the day traders that have overtaken this message board which has become a joke.
you do need to lay off the kool aid. this story has many chapters written long before you found out about cytori. this stock will not run away from you and dilution is coming as they need more cash as they have #$%$ away hundreds of millions of dollars. Our x COB LLyod dean promised us 10x's our wildest dreams and I promise you that there is not a long who has had this stock for a few years that is not completely under water. Technology is real,but management has yet to deliver on any promise.
All old news on Lorem. They have not made much progress yet, don't even have website up.
The photos you showed will never be used as they show old cellution machines which LV will never be selling so not sure what your all excited about. The Japanese law has passed over a year ago and the revenue it has generated has been next to nothing,not like management has promised. Perhaps next earnings report and conference call will bring news but I doubt it.
Shorts will cover then wash rinse repeat, they short again. Been to this dance many times over the last 5 years. Hopefully this new band will put together a string of hits. It's a long road back. But a good day none the less.
Tell us something we all don't know. This board is basically worthless now. No prudent conversation, just bs from paid posters. Not much going on Fas sight either,just hope, prayers and wishful thinking. Until this company has some real sales, real results and not just promises, it's just going to be the same BS it's been for the last 5 years, i've beem involved and the last 15 years that Cytori has existed in one form or another.
Keep pumping but if you watch trades the market makers will not let this run. They are lowering the asks and trading with themselves. Not a day for the individual investor, but probably not a bad entry point but.. can't loose sight that there will be dilution in the not to distant future. Plus $1 does calm some delisiting fears. Perhaps Hedrik may actually be propehetic but the odds are against it.
When pigs fly.Been a stuck holder for 5 years nothing but lies, broken promises and disappointment.It has unfortunately obvious that this pos is nothing more then a datasets wet dream.Only shorts and management getting free options and are completely overpaid have made money.Sad but true.This is a fairy tale gone very bad.
Scleroderma and Osteoarthritis. Cytori continues to diversify the ADRC therapeutic indication with movement in the scleroderma trial. The scleroderma space has 70,000 patients in the US, and Cytori believes that they can take a large market share relatively easily for this unmet need. In osteoarthritis (knee), Cytori is currently evaluating ADRCs in the RECOVER (phase I/II) trial, which is expanding from 10 patients to 90 in 2015. The company has also received approval for an IDE trial in osteoarthritis, which is expected to enroll in 2015.
Urinary Incontinence and Japan. Currently, the Japanese government-sponsored pivotal clinical trial is being reviewed by the MHLW and should commence enrolling in 2015. Also, the new regenerative medicine legislation should favor Cytori, as the ADRCs are already approved as an autologous, POC therapy. This could set the stage for Cytori to capture significant revenues in Japan, a country with four million urinary incontinence patients. Success in Japan could aid in clinical development here in the US (25 million patients).
Valuation. We assume Cytori will be successful in scleroderma and multiple other indications utilizing ADRCs (thermal burns, stress urinary incontinence, and osteoarthritis). We apply a 25% risk cut to our therapeutic model and a 30% discount to financial models for FCFF, discounted-EPS, and SOP to arrive at our new $7.00 price target.
Cytori Therapeutics Inc (CYTX - NASDAQ - $0.59 )
Target Price: $7.00
Enrollment in ACT-OA: US Phase II Trial for Knee Osteoarthritis
Cytori announced that the first patient has been treated in its FDA-approved trial assessing the effect of its adipose-derived, point-of-care cell therapy fraction for osteoarthritis of the knee. The patient was treated by Dr. Peter Hanson, Medical Director of Orthopedic Surgery at Sharp Grossmont Hospital.
ACT-OA is a Phase II, FDA-approved, randomized, double-blind, placebo-controlled trial in n=90 patients evaluating the efficacy and safety of Cytori’s autologous adipose-derived therapy ECCO-50 (Cytori’s therapeutic under study). The trial tests both a low dose and a high dose vs. placebo, and will be conducted over 48 weeks. The randomization will be 1:1:1 between the control, low dose, and high dose groups. The primary endpoint will be pain on walking as measured by the Knee Injury and Osteoarthritis Outcome Score at 12 weeks. Secondary endpoints assessed will include pain, joint function, magnetic resonance imaging, and adverse events.
Conclusion: We see Cytori more focused now on shorter trials that have the potential to provide real proof-of-concept (POC) data in late 2015 and early 2016.
The New Cytori: Lean and Focused. Cytori is waiting for PII POC data to create a value inflection before the company commits to a clinical pathway. Focusing on indications that meet the hurdle, such as OA and Scleroderma, and not those that don't (hamstring injuries), while seeking a partner for others (CV).
Thermal Burns and BARDA. The BARDA contract is worth up to $106M in non-dilutive capital. A $12M contract option was recently executed, and another $8M will come following completion of the pilot clinical trial for burn injury and IDE approval.
Scleroderma and Osteoarthritis. Cytori continues to diversify the ADRC therapeutic indication with movement in the scleroderma trial. The scleroderma space has 70,000 patie
They could buy all the shares for under a buck or oufter bankruptcy if they continue to drown in quick sand.. Wishful thinking .
right now it's worth less the.50. That is realitiy, hopes and dreams when it comes to this mis run company are just that and as my father always told me , you can't eat potential. hundreds of millions of dollars have been spent on R&D and what does Cytori actually have to show for it.. Nothing, compared to where they should be or could be had they been guided by an experienced competant mangement team and BOD. Sorry but as far as myself and I am sure I speak for 99.8% of the longer term holders, to date this has been nothing short of the worst investment any of us have ever made. Show me the money!
They don't even have a functioning web site and just hired an X Cytori manager which can't be good.It's time to put up or shut up already 15 years of complete BS ,mistakes and do overs is enough already. KT lim invested some 26 million in Cytori which they have pi$$ed away, with nothing to show for it. KT LIM isn't buying any shares @ .47 either so perhaps he is just wating to get all the goodies from the BK courts.
Completely irrespondsible of Roth and Kolbert to have such ridiculous targets on this POS. Must mean more dilution is right around the corner.